SWOG clinical trial number
S0502
A Phase III Randomized Study of Imatinib, with or without Bevacizumab (NSC-704865), in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
2% Accrual
Accrual
2%
Closed
Phase
2% Accrual
Accrual
2%
Published
Abbreviated Title
GIST Ph III imatinib with or without bevacizumab
Activated
04/15/2008
Closed
10/01/2009
Participants
Research committees
Gastrointestinal Cancer
Treatment
STI-571/Imatinib
Bevacizumab
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
S2303
SWOG Clinical Trial Number
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
CTSU/A022101
SWOG Clinical Trial Number
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
S2107
SWOG Clinical Trial Number
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
100% Accrual
Accrual
100%
Open
Phase